146 related articles for article (PubMed ID: 35679525)
1. Lorlatinib in Frontline Therapy for ALK+ Advanced Non-Small-Cell Lung Cancer: Still a Matter of Debate?
Pérol M; Swalduz A
J Clin Oncol; 2022 Nov; 40(31):3564-3568. PubMed ID: 35679525
[No Abstract] [Full Text] [Related]
2. [New drug approval: First-line lorlatinib in advanced ALK-positive non-small cell lung cancer].
Pasquier C; Basse C
Bull Cancer; 2022 Sep; 109(9):877-878. PubMed ID: 35717222
[No Abstract] [Full Text] [Related]
3. Lorlatinib as a treatment for ALK-positive lung cancer.
Baba K; Goto Y
Future Oncol; 2022 Aug; 18(24):2745-2766. PubMed ID: 35787143
[TBL] [Abstract][Full Text] [Related]
4.
Shaw AT; Solomon BJ; Besse B; Bauer TM; Lin CC; Soo RA; Riely GJ; Ou SI; Clancy JS; Li S; Abbattista A; Thurm H; Satouchi M; Camidge DR; Kao S; Chiari R; Gadgeel SM; Felip E; Martini JF
J Clin Oncol; 2019 Jun; 37(16):1370-1379. PubMed ID: 30892989
[TBL] [Abstract][Full Text] [Related]
5. The
Ibrahim R; Chahine C; Felefly T; Khalife N; Saleh K
Future Oncol; 2023 Feb; 19(4):273-275. PubMed ID: 36942735
[No Abstract] [Full Text] [Related]
6. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Solomon BJ; Besse B; Bauer TM; Felip E; Soo RA; Camidge DR; Chiari R; Bearz A; Lin CC; Gadgeel SM; Riely GJ; Tan EH; Seto T; James LP; Clancy JS; Abbattista A; Martini JF; Chen J; Peltz G; Thurm H; Ou SI; Shaw AT
Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378
[TBL] [Abstract][Full Text] [Related]
7. First-line lorlatinib for advanced ALK-positive non-small-cell lung cancer.
Lin JJ; Gainor JF
Lancet Respir Med; 2023 Apr; 11(4):302-304. PubMed ID: 36535299
[No Abstract] [Full Text] [Related]
8. Lung cancer: Resolving resistance to ALK-targeted therapy.
Hutchinson L
Nat Rev Clin Oncol; 2016 Feb; 13(2):64. PubMed ID: 26806320
[No Abstract] [Full Text] [Related]
9. Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort.
Baldacci S; Besse B; Avrillon V; Mennecier B; Mazieres J; Dubray-Longeras P; Cortot AB; Descourt R; Doubre H; Quantin X; Duruisseaux M; Monnet I; Moro-Sibilot D; Cadranel J; Clément-Duchêne C; Cousin S; Ricordel C; Merle P; Otto J; Schneider S; Langlais A; Morin F; Westeel V; Girard N
Eur J Cancer; 2022 May; 166():51-59. PubMed ID: 35278825
[TBL] [Abstract][Full Text] [Related]
10. A pragmatic guide for management of adverse events associated with lorlatinib.
Liu G; Mazieres J; Stratmann J; Ou SI; Mok T; Grizzard M; Goto Y; Felip E; Solomon BJ; Bauer TM
Lung Cancer; 2024 May; 191():107535. PubMed ID: 38554546
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological and clinical properties of lorlatinib in the treatment of
El Darsa H; Abdel-Rahman O; Sangha R
Expert Opin Pharmacother; 2020 Sep; 21(13):1547-1554. PubMed ID: 32511029
[TBL] [Abstract][Full Text] [Related]
12. LTK mutations responsible for resistance to lorlatinib in non-small cell lung cancer harboring CLIP1-LTK fusion.
Mori S; Izumi H; Araki M; Liu J; Tanaka Y; Kagawa Y; Sagae Y; Ma B; Isaka Y; Sasakura Y; Kumagai S; Sakae Y; Tanaka K; Shibata Y; Udagawa H; Matsumoto S; Yoh K; Okuno Y; Goto K; Kobayashi SS
Commun Biol; 2024 Apr; 7(1):412. PubMed ID: 38575808
[TBL] [Abstract][Full Text] [Related]
13. Continuation of Lorlatinib in ALK-Positive NSCLC Beyond Progressive Disease.
Ou SI; Solomon BJ; Shaw AT; Gadgeel SM; Besse B; Soo RA; Abbattista A; Toffalorio F; Wiltshire R; Bearz A
J Thorac Oncol; 2022 Apr; 17(4):568-577. PubMed ID: 35026476
[TBL] [Abstract][Full Text] [Related]
14. Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer.
Shiba-Ishii A; Johnson TW; Dagogo-Jack I; Mino-Kenudson M; Johnson TR; Wei P; Weinrich SL; McTigue MA; Walcott MA; Nguyen-Phuong L; Dionne K; Acker A; Kiedrowski LA; Do A; Peterson JL; Barth JL; Yeap BY; Gainor JF; Lin JJ; Yoda S; Hata AN
Nat Cancer; 2022 Jun; 3(6):710-722. PubMed ID: 35726063
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Lorlatinib Cerebrospinal Fluid Concentrations in Relation to Target Concentrations for Anaplastic Lymphoma Kinase (ALK) Inhibition.
Sun S; Pithavala YK; Martini JF; Chen J
J Clin Pharmacol; 2022 Sep; 62(9):1170-1176. PubMed ID: 35373356
[TBL] [Abstract][Full Text] [Related]
16. Acquired G2032R Resistance Mutation in ROS1 to Lorlatinib Therapy Detected with Liquid Biopsy.
Jóri B; Falk M; Hövel I; Weist P; Tiemann M; Heukamp LC; Griesinger F
Curr Oncol; 2022 Sep; 29(9):6628-6634. PubMed ID: 36135089
[TBL] [Abstract][Full Text] [Related]
17. Lorlatinib Is Active in Drug-Resistant NSCLC.
Cancer Discov; 2016 Aug; 6(8):OF1. PubMed ID: 27401797
[TBL] [Abstract][Full Text] [Related]
18. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
Lin YT; Chiang CL; Hung JY; Lee MH; Su WC; Wu SY; Wei YF; Lee KY; Tseng YH; Su J; Chung HP; Lin CB; Ku WH; Chiang TS; Chiu CH; Shih JY
Eur J Cancer; 2021 Oct; 156():1-11. PubMed ID: 34392186
[TBL] [Abstract][Full Text] [Related]
19. In-depth Analysis of Lorlatinib-related neurocognitive Adverse Events in Patients With Non-small-cell Lung Cancer.
Schoenmaekers J; Dijkstra J; van der Wekken A; Paats M; Broen M; Brandts L; Dingemans AM; Hendriks L
Clin Lung Cancer; 2024 Mar; 25(2):168-174.e1. PubMed ID: 38151408
[TBL] [Abstract][Full Text] [Related]
20. Crizotinib Resensitization by Compound Mutation.
Bordi P; Del Re M; Tiseo M
N Engl J Med; 2016 May; 374(18):1790. PubMed ID: 27144863
[No Abstract] [Full Text] [Related]
[Next] [New Search]